. Author manuscript; available in PMC: 2020 Apr 24.

Published in final edited form as: Obstet Gynecol. 2019 Apr;133(4):795–802. doi: 10.1097/AOG.0000000000003171

Table 3.

Base case costs and outcomes related to selected strategies for platinum-sensitive recurrent ovarian cancer

Strategy	Cost/patient ($)	PF-QALY Benefit/patient (months)	PF-QALY Benefit/patient (years)	Incremental cost-effectiveness ratio ($/PF-QALY)^*	Additional annual cost to US health system ($)^**
Observation	$827	3.4	0.29	--	--
gBRCA testing/selective treatment	$46,157	5.7	0.48	$243,092/PF-QALY	$ 249 million
gBRCA testing + HRD testing/selective treatment	$109,368	8.5	0.71	$269,883/PF-QALY	$ 597 million
Treat all	$169,127	8.8	0.74	$2.2 million/PF-QALY	$ 926 million

All ICERs refer to a comparison to the next less effective strategy in Table. The ICER threshold for considering a strategy cost effective was $100,000/PF-QALY.

^**

Assuming 5,507 platinum sensitive recurrent ovarian cancer patients annually.